The global obesity crisis has sparked a multibillion-dollar showdown in the pharmaceutical world, with Novo Nordisk and Eli Lilly locked in an intense battle for supremacy. These industry titans are redefining the weight loss drug market with groundbreaking GLP-1 therapies. Novo Nordisk’s WEGOVY (semaglutide) and Eli Lilly’s ZEPBOUND (tirzepatide) are reshaping the anti-obesity drug market—but which powerhouse will claim the top spot in this high-stakes race?
Obesity Drug Market Overview and Growth Potential
The US obesity drug market is on a meteoric rise, projected to soar past USD 73 billion by 2034. This explosive growth is driven by surging obesity rates, a...
